  The increasingly pressing demand of novel drugs (e.g., gene therapies for
personalized cancer care, ever evolving vaccines) with unprecedented levels of
personalization, has put a remarkable pressure on the traditionally long time
required by the pharma R&D and manufacturing to go from design to production of
new products. The revolution has already brought important changes in the
technologies used within the industry. In fact, practitioners are increasingly
moving away from the classical paradigm of large-scale batch production to
continuous biomanufacturing with flexible and modular design, which is further
supported by the recent technology advance in single-use equipment. In contrast
to long design processes, low product variability (one-fits-all), and highly
rigid systems, modern pharma players are answering the question: can we bring
design and process control up to the speed that novel production technologies
give us to quickly set up a flexible production run?
  In this tutorial, we present key challenges and potential solutions from the
world of operations research that can support answering such question. We first
present technical challenges and novel methods for the design of next
generation drugs, followed by the process modeling and control approaches to
successfully and efficiently manufacture them.
